Absci Corp
ABSI
Company Profile
Business description
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Contact
18105 SE Mill Plain Boulevard
VancouverWA98683
USAT: +1 360 949-1041
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
140
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,134.70 | 72.50 | -0.79% |
| CAC 40 | 8,485.64 | 77.37 | 0.92% |
| DAX 40 | 25,612.03 | 151.55 | 0.60% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,897.27 | 11.14 | -0.10% |
| HKSE | 25,800.27 | 58.61 | -0.23% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 64,268.24 | 2,400.81 | 3.88% |
| NZX 50 Index | 13,699.28 | 63.50 | -0.46% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,975.00 | 74.90 | -0.83% |
| SSE Composite Index | 3,838.45 | 33.76 | 0.89% |